HOME >> BIOLOGY >> NEWS
Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair

Hawthorne, NY December 19, 2002 Acorda Therapeutics announced today that it has been awarded a two-year Phase 2 Small Business Technology Transfer (STTR) grant from the National Institutes of Health. The $980,000 grant will continue to fund collaborative research between Acorda and Drs. Allan Bieber and Moses Rodriguez of Mayo Clinic. The grant will fund research at Acorda and at Mayo Clinic to advance the development of a class of naturally occurring human IgM antibodiesfor further preclinical testing in multiple sclerosis (MS). Upon successful completion of the aims of the study, Acorda expects to file an IND (investigational new drug application) with the FDA to begin clinical testing of these antibodies.

When myelin, the "insulation" surrounding nerve fibers, is lost or damaged, the nerve loses its ability to transmit signals to and from the brain. This loss of myelin can result in varying levels of disability, such as cognitive deficits, difficulty in walking and fatigue.

Under the support of a Phase 1 STTR grant, Acorda and Mayo Clinic tested the two antibodies under study (sHIgM22 and sHIgM46) using a widely accepted animal model. Mice were injected with a virus that causes demyelination in the nervous system and then received treatment with the study antibodies after the onset of demyelination. The antibody treatment produced a robust remyelination in these mice.

"Current MS therapies work by slowing the progression of the disease but do not address the permanent demyelination that leads to the disabilities associated with that condition. The antibodies being studied act to stimulate the regrowth of myelin, thereby offering an entirely new type of therapeutic approach in the treatment of MS," said Eric Chojnicki, Ph.D., Acorda's Director of Product Development, and the principal investigator on the grant.

"Our results indicate that these antibodies are part of the normal immune response in humans that may help protec
'"/>

Contact: Tierney Saccavino, Acorda Therapeutics
tsaccavino@acorda.com
914-347-4300
Porter Novelli
20-Dec-2002


Page: 1 2

Related biology news :

1. Acorda Therapeutics acquires CeNeS neuregulin products
2. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
3. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
4. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
5. Molecular therapeutics advance fight against brain cancer
6. Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics
7. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
8. Immerge biotherapeutics identifies miniature swine that do not transmit pig retrovirus to humans
9. Polymer gel holds promise for therapeutics delivery and tissue engineering
10. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/22/2019)... (PRWEB) , ... October 21, 2019 , ... Join ... MS, Director of Bioanalytical in a live session on Thursday, October 31, ... CRO partner. , A good CRO partner should have expertise in method development, ...
(Date:10/17/2019)... (PRWEB) , ... October 15, 2019 , ... ... Prepared Media for the Microbiological Community”. , Microbiology International currently manufactures ready-to-use culture ... company also offers pre-poured agar plates & liquid supplements. , This major step ...
(Date:10/15/2019)... ... 2019 , ... Erchonia, the global leader in the manufacturing ... in Orlando & 18th Annual Golf Tournament. The invite-only, four-day event starts ... Melbourne. , The first day will kick off with training and roundtable discussions ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... ... September 24, 2019 , ... Drug resistance has been declared ... Health Organization, with MRSA becoming one of the most serious concerns. Hong Kong cannot ... cases of community-associated MRSA (CA-MRSA), or a seven-fold of the figure in 2007 – ...
(Date:9/24/2019)... , ... September 24, 2019 , ... In the past ... research led by faculty at South Dakota School of Mines & Technology ... microbes that attach to surfaces to form a slimy and yet strong layer which ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a Rochester ... today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office ... class recommendations for hypertension treatment. , The patent applies to Geneticure’s first ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... was co-located with the China Focus @ Biotech Week Boston, a forum organized ... and collaborations in healthcare innovation. , After a careful process of evaluation, twelve ...
Breaking Biology Technology:
Cached News: